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OBJECTIVES: Gastro esophageal reflux disease (GERD) is commonly associated
with a significant adverse impact on the patient’s quality of life, his/her employ-
ment record, and healthcare systems. The aim of this analysis was to conduct a
pooled analysis of the data from five European studies (GERDManagement Project)
to assess the potential benefit for healthcare providers of a structured treatment
pathway (STP) for the treatment of GERD.METHODS:We conducted a meta-anal-
ysis of five cluster randomised clinical trials comparing a new management strat-
egy with usual care in patients with GERD conducted in Austria, Italy, Norway,
Spain and Sweden (NCT00842387). The educational intervention on investigators
was based on the GerdQ questionnaire to stratify adult patients with classical
symptoms of GERD according to the frequency and impact of symptoms. Themost
effective acid-suppressive therapy (esomeprazole 40 mg once daily) was proposed
to be used only in patients with the highest GerdQ symptom impact score (3 of a
possible 6). Calculations were performed using data on mean values for resource
utilization (including emergency room visits, hospitalization, primary-care physi-
cian visits, specialist visits and endoscopies) multiplied by the unit cost of each
variable. UK unit costs were applied to the entire European cohort. RESULTS: 1947
patients were included in the analysis, 944 (49%) on the STP group and 1003 (51%)
on the usual clinical practice (UCP) group. In the STP group, GerdQ scores improved
significantly more during therapy than in the UCP group. Patients in the STP group
had lower overall healthcare costs, 107.59€ per patient/year, than those in the UCP
group, 137.55€ per patient/year (i.e. 22% reduction in healthcare utilization costs).
CONCLUSIONS: The implementation of a structured treatment pathway for the
treatment of GERD based in the GerdQ questionnaire could considerably reduce
the disease healthcare utilization costs compared with the usual clinical prac-
tice.
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PATIENT CHARACTERISTICS ASSOCIATED WITH USE OF ENTERAL VERSUS
PARENTERAL ACID SUPPRESSIVE AGENTS IN INTENSIVE CARE UNIT PATIENTS
Sankaranarayanan J, Reardon T, Olsen KM
University of Nebraska Medical Center, Omaha, NE, USA
OBJECTIVES: Administering acid suppressive therapy, AST (proton pump inhibi-
tors, PPIs or H2 receptor antagonists, H2RAs) via enteral versus parenteral route in
Intensive Care Unit (ICU) patients for stress ulcer prophylaxis (SUP)may save costs.
As little is known on who can receive enteral vs. parenteral AST, our objective was
to evaluatewhether ICUpatients on any oralmedication orwith an oro-gastric tube
receive enteral versus parenteral AST.METHODS: In a retrospective study of elec-
tronic medical record data,  19-year-old adult patients admitted to a Midwest
AcademicMedical Center’s ICU and receiving anAST in 2008were included. Patient
data {age, gender, nonoperative/postoperative status, any oralmedication use, oro-
gastric tube, nothing by oral route (NPO), resource utilization variables (hospital
days, ICU days) and AST-use (enteral/parenteral)} were collected. Statistical differ-
ences between enteral and parenteral AST (PPI and H2RA) patient groups were
determined using Chi-square or fisher’s exact test and Wilcoxon-rank-sum tests.
In multivariate logistic regression analyses, the association of patient characteris-
tics (any oral medication use, oro-gastric tube, NPO) with enteral versus parenteral
AST-use was tested. P0.05 was considered statistically significant. RESULTS: 54%
and 43% of PPI (n392) and H2RA (n203) patients, respectively received drug
through enteral route. The enteral and parental H2RAs groups did not differ by any
characteristics. The enteral and parental PPI groups differed significantly by me-
dian hospital days (8.0 versus 13.0), median ICU days (2.0 versus 4.0), and nonop-
erative/postoperative patient-status (55%/45% versus 41%/59%). Inmultivariate lo-
gistic regression analyses, any oral medication use increased the likelihood of
enteral versus parenteral H2RA-use (P0.05) and PPI-use (P0.0001); however use
of an orogastric tube was not significantly associated. CONCLUSIONS: To realize
cost-effective quality of care, patients with an orogastric tube could receive enteral
instead of parenteral AST and further study of cost savings from such use is un-
derway.
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OBJECTIVES: This study examined comparative safety of stimulant versus atom-
oxetine with the risk of neurological adverse events in children with Attention-
Deficit/Hyperactivity Disorder (ADHD). METHODS: The IMS LifeLink Health Plan
Claims Database was used for this retrospective, propensity score matched analy-
sis of children and adolescents with ADHD on stimulant and atomoxetine. The
study sample included children less than 18 years of age initiating stimulant or
atomoxetine therapy between July 1, 2004 to December 31, 2005. Patients with
stimulant and atomoxetine were matched on propensity scores calculated based
on baseline characteristics. The neurological adverse events included tics disorder
(ICD-9-CM code-307.2x) and seizures (ICD-9-CM codes- 345.xx, 780.3, 780.39,
780.31). Conditional logistic regression was used to account for the matched pair
design. The final logistic model was adjusted for duration of therapy/persistency
alongwith other covariateswhichwere significant aftermatching. Sensitivity anal-
ysis was also performed using pharmacotherapy as themain outcomemeasure for
management of neurological adverse events. RESULTS: The propensity score
matched cohort consisted of a total of 7,424 children with ADHD (3,712-Atomox-
etine users and 3,712-Stimulant users). Conditional logistic regression revealed
that stimulant or atomoxetine use did not differ in terms of the risk of neurological
adverse events development (Odds Ratio [OR]- 0.86; 95% Confidence Interval [CI]-
0.57-1.28). However, central nervous systempathologywas significantly associated
with the development of neurological adverse events (OR-2.87; 95% CI-1.19-6.92).
Sensitivity analysis showed that stimulant use (OR-1.36; 95% CI- 1.18-1.56) was
positively associated with the treatments for neurological adverse events.
CONCLUSIONS: Stimulant use was not significantly associated with diagnosis of
neurological adverse events compared to atomoxetine in children. However, sen-
sitivity analysis revealed that the stimulant users had an increased chance of
receiving treatments for neurological adverse events. The findings suggest that
stimulant use can lead to neurological adverse events which are not documented
in ADHD patients but are usually treated.
PMH2
RISK OF HOSPITALIZATION FOR PNEUMONIA ASSOCIATED WITH THE USE OF
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OBJECTIVES: To evaluate the risk of hospitalization for pneumonia associatedwith
typical and atypical antipsychotic use in an elderly Medicare population.
METHODS: This retrospective cohort study used two years (2006-2007) of 5% na-
tional sample ofMedicare claims data. Medicare beneficiarieswith continuous Part
A, B, and D enrollment in 2006-2007 and who initiated atypical or typical antipsy-
chotic drug therapy during July 2006-June 2007 were identified from Part D claims
data. Propensity score matching was used to control for potential confounding. A
conditional logistic regression model stratified on propensity score-matched pair
was used to compare the risk of hospitalization for pneumonia in new users of
atypical vs. typical antipsychotic drugs within a 180 day follow-up period starting
from the date of first prescription. RESULTS: A total of 15,637 new users of atypical
and 2,337 new users of typical antipsychotic drugs were identified July 2006-June
2007. A total of 1,363(7.6%) subjects had a hospitalization for pneumonia during
follow-up. The proportion of hospitalizations was similar in the atypical (7.5%) and
the typical antipsychotic (8.0%) groups. A total of 2,335 propensity score-matched
pairs were obtained using the Greedy 5-1 matching algorithm. In the matched
cohort, there were 186 (7.97%) pneumonia hospitalizations in typical users com-
pared to 179 (7.67%) among atypical users. Typical antipsychotics users did not
differ significantly from atypical users on the risk of pneumonia (odds ratio: 1.042,
95% CI: 0.843-1.288). Sensitivity analysis using propensity score as a continuous
variable in a multivariable logistic regression model yielded similar results (odds
ratio: 0.976, 95% CI: 0.828-1.150). CONCLUSIONS: The risk of hospitalization for
pneumonia was similar for new users of typical and atypical antipsychotic drugs.
While this indicates that there is no added safety concern for users of atypical
antipsychotics, it also suggests there is no added advantage of atypical use, espe-
cially in patients at high risk for pneumonia.
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OBJECTIVES: To study the association between the type of antipsychotic drug use
and the occurrence of hip fracture in an elderly Medicare population. METHODS:
Two years (2006-2007) of 5% national sample of Medicare claims data were used to
conduct this population-based retrospective cohort study. Medicare beneficiaries
with continuous Part A, B, and D enrollment in 2006-2007 and who initiated atyp-
ical or typical antipsychotic therapy July 2006 -June 2007 were identified from Part
D claims data. All study subjects were followed for 180 days from index date, the
date of first antipsychotic prescription. Propensity scores were calculated for each
individual using pre-index demographics, comorbidities, and medication use. Us-
ers of atypical antipsychotics and typical antipsychotics werematched on propen-
sity score using the Greedy 5-1matching algorithm. Conditional logistic regression
model stratified on propensity score-matched pair was used to compare the risk of
hospitalization for hip fracture in new users of atypical versus typical antipsy-
chotic drugs; sensitivity analysis was conducted using propensity score as a con-
tinuous, linear term in the unmatched study cohort using logistic regression.
RESULTS: 15,637 new users of atypical and 2,337 new users of typical antipsychotic
drugs were identified. 307 (1.7%) of all antipsychotic users had a hospitalization for
hip fracture during follow-up. Of these, 40were typical and 267were atypical users.
In the propensity score-matched cohort of 4,660 individuals (2,330 pairs), 40 (1.72%)
typical antipsychotic users and 38 (1.63%) atypical antipsychotic users had a hos-
pitalization for hip fracture during follow-up. The risk of hip fracturewas not found
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to be statistically significant (odds ratio: 1.056; 95%CI: 0.669-1.665) between atypical
and typical antipsychotic users. Similar results were obtained in sensitivity anal-
ysis (odds ratio: 1.089; 95% CI: 0.775-1.530). CONCLUSIONS: Typical and atypical
antipsychotic drug use in an elderly Medicare population has similar risks of hip
fracture.
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ANTIPSYCHOTICS-A MULTIPLE PROPENSTY SCORE ADJUSTED RETROSPECTIVE
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OBJECTIVES:The study evaluated the risk of falls and fractures associatedwith use
of risperidone, olanzapine and quetiapine among community-dwelling older
adults in the US. METHODS: The study involved a multiple propensity score-ad-
justed retrospective cohort design and included older adults aged 50 years and
above, who initiated prescriptions of risperidone, olanzapine or quetiapine be-
tween July 1, 2000 and June 30, 2008 using IMS LifeLink Health Plans Claims data-
base. Patients were followed until hospitalization/emergency room (ER) visit for
accidental fall/hip fracture, or the end of the study period, whichever occurred
earlier. Propensity score-adjusted Cox proportional hazard regression model was
used to evaluate the relative risk of falls or fractures. The covariates in the final
model included maximum dose of antipsychotic therapy, and exposure to other
psychotropic medications that increase the risk of falls or fractures. RESULTS:
There were 12,145 (5,083 risperidone, 4,377 olanzapine and 2,685 quetiapine) new
users of atypical agents. A total of 380 cases of falls or fractures with at least one
hospitalization/ ER visit following the use of antipsychotic agents were identified.
The number of falls or fractures for risperidone, olanzapine and quetiapine were
165 (3.65%), 109 (2.81%) and 106 (4.47%) respectively. After adjusting for propensity
scores and other covariates, the Cox proportional hazardmodel showed that there
was no statistically significant difference with use of risperidone (hazard ratio,
HR-1.11; 95% CI- 0.85-1.45) or quetiapine (HR-1.16; CI-0.87-1.53) compared to olan-
zapine in the risk of falls or fractures. CONCLUSIONS: The study found no signifi-
cant difference across the individual atypical agents in the risk of falls or fractures
in a large cohort of older adults. Future studies are required to evaluate the overall
safety profiles of atypical antipsychotics in the above population.
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OBJECTIVES: Attention deficit hyperactivity disorder (ADHD) is a common psychi-
atric disorder of childhood, and the methylphenidate hydrochloride (MPH) is the
most frequently and well-established prescribed pharmacotherapy for ADHD.
Warnings by the United States Food and Drug Administration on psychiatric ad-
verse effects have concerns for drug safety. Existing studies to date demonstrate
that MPH’s safety of children with ADHD which get inconsistent results. The pur-
pose was to evaluate the potential association between MPH treatment and the
subsequent development of psychiatric disorders such as disruptive, anxiety,
mood, learning, tic and substance-related disorders. METHODS: A retrospective
cohort studywas conducted. Study subjects selectedwere aged 6 to 18 years on the
date of the first diagnosed for ADHD between 2001 and 2006. Patients were divided
into 2 groups: ever-using MPH and not-using MPH. The authors conducted case-
control matching on the propensity score to reduce selection bias. The Cox Propor-
tional Hazards Model was used to assess the association of use of MPH with the
subsequent risks of psychiatric events occurring. RESULTS: The results shows that
the MPH group had a significantly higher hazard ratio (HR) of patients diagnosed
with oppositional defiant disorder (ODD) (HR  1.807, P  0.001), conduct disorder
(CD) (HR 1.225, P 0.0460), and anxiety disorders (AD) (HR 1.921, P 0.001). The
MPH group had a significantly lower HR of patients diagnosed with learning disor-
ders (LD) (HR 0.818, P 0.0029). In addition, the authors found theMPH group had
a significantly higher HRs of ODD and CD and a significantly lower HR of LD in boys
only. CONCLUSIONS: Our study found that MPH treatment is associated with a
higher risk of development of oppositional defiant disorder, conduct disorder and
anxiety disorders and a lower risk of learning disorders.
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DIFFERENTIAL RATES OF SIDE EFFECTS IN DEPRESSED ADULTS AND
ADOLESCENTS BEING TREATED WITH ANTIDEPRESSANTS
Anderson HD, Libby AM, Pace WD, West DR, Valuck RJ
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OBJECTIVES: Antidepressants are first line treatment for depression. Effectiveness
may be compromised because of discontinuation, which is commonly associated
with side effects. Using a national database of medical and pharmacy claims, we
sought to identify and compare the prevalence of side effects in newly depressed
adult and adolescent patients taking different classes of antidepressants.
METHODS: A new-user design was implemented using 11 years of data to identify
a retrospective cohort of newly depressed subjects on antidepressant mono-
therapy, defined as SSRI, SNRI, TCA, MAOI, buproprion, phenylpiperazine, or tet-
racyclic. Rates of side effects (per 1,000 person-months of exposure) were calcu-
lated within each antidepressant group; relative risks were calculated (SSRI as
referent group). Propensity-adjusted Cox Proportional Hazards regression was
used to model the likelhood of side effects adjusted for demographic, clinical and
treatment characteristics. RESULTS:A total of 40,017 patients had a new episode of
depression and were on antidepressant monotherapy within 30 days of diagnosis
[SSRI (66%), Bupropion (14%), SNRI (12%), other (8%)]. Themost common side effects
were headache (up to 16.8 per 1,000 person-months of therapy in adults, 17.6 per
1,000 in adolescents) and nausea (up to 7.2 per 1,000 in adults, 9.3 per 1,000 in
adolescents). Relative to adults receiving SSRIs, those receiving SNRIs had higher
risk of nausea (HR1.28, 95%CI1.08-1.52), and of having one ormore side effect of
any type (HR1.23, 95%CI1.10-1.37). Adults taking bupropion were less likely to
have sedation (HR0.36, 95%CI0.16-0.79). Adolescent receiving an SNRI were
more likely to experience sedation compared to adolescents receiving an SSRI
(HR3.14, 95%CI1.01-9.82). CONCLUSIONS: Side effects detected in claims must
be significant enough to be reported to the provider and medically coded, so these
rates are underestimates. Nevertheless, the reported rates are nontrivial. Future
work will account for side effects in the likelihood of discontinuation and associ-
ated reduced comparative effectiveness.
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OBJECTIVES: Selective Serotonin Reuptake Inhibitors (SSRIs) are widely used anti-
depressants. Pharmacokinetic and pharmacodynamic differences among the SS-
RIs can give rise to differences in drug-drug interaction (DDI) potential. This study
estimated the effect of initial SSRI choice on the likelihood of receiving a potentially
interacting drug (and thus a potential SSRI-DDI) among subjects initiating therapy
with SSRIs in the United States managed health care plans. METHODS: Using a
large health insurance claims database (IMS LifeLink Database), we examined ret-
rospective cohorts of new SSRI users between 2002-2008. For each new SSRI user,
we used medical and pharmacy claims to identify instances and crude rates of
potential SSRI-DDI according to compendia and expert panel based lists of inter-
actions. We calculated crude and adjusted incidence rate ratios for potential SSRI-
DDI based on the initial SSRI prescribed, adjusting for demographic, clinical, and
prescriber related factors, length of SSRI exposure and propensity for receiving
escitalopram as the initial SSRI using Poisson regression methods. RESULTS: A
total of 913,619 subjects met inclusion criteria. Using the compendia list of SSRI-
DDI, 48.5-62.0% of subjects had at least one instance of coprescribing of potentially
interacting drug(s) with SSRI. Compared to escitalopram users, citalopram (HR
[Hazard Ratio]1.05, p0.01), fluoxetine (HR1.03, p0.01), fluvoxamine (HR1.17,
p0.01), and paroxetine (HR1.05, p0.01) users all demonstrated a higher likeli-
hood of potential SSRI-DDI. Sertraline (HR0.99, p0.32) users demonstrated a
similar likelihood of potential SSRI-DDI as escitalopram. Results were similar for
the expert panel list of SSRI-DDI. CONCLUSIONS: SSRIs are widely used, and co-
prescribing of drugs with the potential to elicit SSRI-DDI may be more frequent
than is often reported. Among SSRIs, escitalopram and sertraline are associated
with a lower likelihood of being co-prescribed with a potentially interacting drug.
Clinicians, pharmacists and patients should be aware of the potential for such
interactions, and further study is needed to identify subsequent patient outcomes.
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EFFECT OF VARIOUS ANTIDEPRESSANT GROUPS ON BONE MINERAL DENSITY
(BMD)
Kurmanji JM1, Syed Sulaiman SA1, Chandrasekaran PK2, Kah LK3
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OBJECTIVES: Research shows a significant association between low bone mineral
density (BMD) and persons receiving antidepressant medication, with levels of
BMD loss varying with the type of pharmacological agent used. This study com-
pared the BMD of depressed patients on different groups of antidepressants.
METHODS: One hundred forty male and female depressed subjects between the
ages of 25 – 70 years were recruited from the psychiatric clinics in Penang General
Hospital and Penang Adventist Hospital. The groups of antidepressant medication
included selective serotonin reuptake inhibitors (SSRI), tricyclic antidepressants
(TCA) and other types of antidepressants (OTA). BMD was ascertained by measur-
ing the quantitative ultrasound derivative Z-score from the calcaneal bone of the
heel using an Ultrasound bone densitometer by Furuno Electric. RESULTS: ANOVA
found no significant differences in mean BMD across the different groups of anti-
depressants (p=0.055). CONCLUSIONS: This study finds no association between
BMD loss and the type of antidepressant employed in a depressed Malaysian pop-
ulation.
PMH9
RISK OF DEATH IN DUAL ELIGIBLE NURSING HOME RESIDENTS USING
ANTIPSYCHOTIC AGENTS
Aparasu RR, Mehta S, Chen H
University of Houston, Houston, TX, USA
OBJECTIVES: Antipsychotic use among dual eligible nursing home residents is a
cost and safety concern. This study examined the comparative risk of death in dual
eligible elderly nursing home residents using typical and atypical agents.
METHODS:A retrospective cohort designmatched on propensity scorewas used to
examine the risk of death due to antipsychotic use among dual eligible nursing
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